Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study
The Lancet Microbe · 2026-03 · 7 (3) · 101283
DOI: 10.1016/j.lanmic.2025.101283 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2026-03. Verfasst von Onyema Ogbuagu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: onyema.ogbuagu@yale.edu. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Quinolones. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Inc.
Abstract (Originalsprache)
BACKGROUND: In a phase 1b study (NCT04811040), lenacapavir combined with the broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab maintained virological suppression (HIV-1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: onyema.ogbuagu@yale.edu.
- St Jude Children's Research Hospital, Memphis, TN, USA.
- Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
- AXCES Research Group, Santa Fe, NM, USA.
- Clinical Research Puerto Rico, San Juan, Puerto Rico.
- Department of Medicine, Emory University, Atlanta, GA, USA.
Förderung
- Gilead Sciences Inc
Zitieren
APA
Ogbuagu, O., Gaur, A., McMahon, J. H., Gorgos, L., Morales-Ramirez, J. O., Workowski, K., Brunetta, J., Mponponsuo, K., Collins, S. E., VanderVeen, L. A., Zhang, N., Huang, H., Baeten, J. M., & Eron, J. (2026). Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. The Lancet Microbe, 7(3), 101283. https://doi.org/10.1016/j.lanmic.2025.101283
Vancouver
Ogbuagu O, Gaur A, McMahon JH, Gorgos L, Morales-Ramirez JO, Workowski K, et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. The Lancet Microbe. 2026;7(3):101283. doi:10.1016/j.lanmic.2025.101283
BibTeX
@article{Ogbuagu2026,
author = {Ogbuagu, Onyema and Gaur, Aditya and McMahon, James H and Gorgos, Linda and Morales-Ramirez, Javier O and Workowski, Kimberly and Brunetta, Jason and Mponponsuo, Kwad and Collins, Sean E and VanderVeen, Laurie A and Zhang, Nan and Huang, Hailin and Baeten, Jared M and Eron, Joseph},
title = {Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {3},
pages = {101283},
doi = {10.1016/j.lanmic.2025.101283}
}
EUVIMED